首页> 外文期刊>International journal of molecular medicine >Intracellular-delivery of a single-chain antibody against hepatitis B core protein via cell-penetrating peptide inhibits hepatitis B virus replication in vitro
【24h】

Intracellular-delivery of a single-chain antibody against hepatitis B core protein via cell-penetrating peptide inhibits hepatitis B virus replication in vitro

机译:抗乙肝核心蛋白的单链抗体通过细胞穿透肽的细胞内传递抑制了乙肝病毒的体外复制

获取原文
           

摘要

Assembly of nucleocapsids is an attractive target for novel anti-hepatitis?B virus (HBV) agents, and intracellular single-chain variable fragment (scFv) antibodies against HBV core (HBc) protein are a class of potential alternatives for this purpose; however, their application is limited by the lack of a suitable means of delivery. Owing to the favorable performance of cytoplasmic transduction peptide (CTP) in cargo delivery in hepatocytes, we purified an anti-HBc scFv fused to CTP using a previous screened sequence by a prokaryotic expression system and evaluated its efficacy in the inhibition of HBV in?vitro. Our results showed that cytoplasmic translocation of the previous anti-HBc scFv was achieved by CTP in HepG2.2.15 cells. Immunoprecipitation analysis indicated the fusion protein anti-HBc scFv-CTP interacted with its target antigen HBc, and negligible cytotoxicity was observed. Moreover, the anti-HBc scFv-CTP interfered with nucleocapsid assembly and markedly reduced both the supernatant HBV DNA level and the intracellular DNA replication intermediates, with a 5.1?μM of half maximal effect concentration and a dose-dependent effect. In conclusion, this novel anti-HBc scFv fused to CTP demonstrated inhibitory activity of HBV replication in?vitro and warrants further in?vivo study.
机译:核衣壳的组装是新型抗乙型肝炎病毒(HBV)药物的诱人靶标,针对此目的,针对HBV核心(HBc)蛋白的细胞内单链可变片段(scFv)抗体是一类潜在的替代选择;然而,由于缺乏合适的递送手段,它们的应用受到了限制。由于细胞质转导肽(CTP)在肝细胞货物运输中的良好性能,我们使用原核表达系统通过先前筛选的序列纯化了与CTP融合的抗HBc scFv,并评估了其体外抑制HBV的功效。 。我们的结果表明,以前的抗HBc scFv的细胞质易位是通过CTP在HepG2.2.15细胞中实现的。免疫沉淀分析表明,融合蛋白抗-HBc scFv-CTP与其靶抗原HBc相互作用,观察到的细胞毒性可忽略不计。而且,抗HBc scFv-CTP干扰了核衣壳的组装,并显着降低了上清液HBV DNA水平和细胞内DNA复制中间体,最大有效浓度为5.1μm,剂量依赖性。总之,这种与CTP融合的新型抗HBc scFv在体外显示出对HBV复制的抑制活性,值得进一步的体内研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号